| product Name |
Mobocertinib succinate |
| Synonyms |
Mobocertinib succinate;788Succinic acid;TAK788 succinate;TAK-788 Succinic acid;Mopotinib succinate;obocertinib Succinate (TAK-788 Succinate);Mobocertinib Succinate (TAK-788 Succinate);Mobocertinib succinate（TAK788） |
| Molecular Formula |
C36H45N7O8 |
| Molecular Weight |
703.8 |
| InChIKEY |
YXYAEUMTJQGKHS-UHFFFAOYSA-N |
| CAS Registry Number |
2389149-74-8 |
| EINECS |
|
| Molecular Structure |
|
| Description |
Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research. |
| Uses |
Mobocertinib is an oral targeted therapy drug[1].Mobocertinib is used to treat a ce Uses rtain type of non-small cell lung cancer (NSCLC) that cannot be removed by surgery and has spread to other parts of the body either during or after treatment with platinum chemotherapy medications. |
Reviews
There are no reviews yet.